Table 1.
Characteristic | No. (%),or median [interquartile range] | P | ||
---|---|---|---|---|
e13a2 | e14a2 | e13a2 and e14a2 | ||
N | 200 (42) | 196 (41) | 85 (18) | |
Age, years [range] | 47 [37-57] | 49 [39-58] | 52 [41-61] | .11 |
Hemoglobin (g/dL) | 12 (11-13) | 12 (11-13) | 13 (12-14) | .32 |
WBC (K/µL) | 31 (12-71) | 28 (17-63) | 30 (13-70) | .94 |
Platelet (K/µL) | 288 (200-418) | 405 (276-592) | 358 (268-493) | .001 |
Sokal score | ||||
High | 11 (5) | 11 (6) | 9 (11) | .53 |
Intermediate | 47 (23) | 48 (24) | 21 (25) | |
Low | 142 (71) | 137 (70) | 55 (65) | |
Treatment type | ||||
Imatinib 400 mg | 31 (15) | 28 (14) | 10 (12) | .32 |
Imatinib 800 mg | 82 (41) | 89 (45) | 28 (33) | |
Dasatinib | 41 (20) | 38 (19) | 26 (31) | |
Nilotinib | 46 (23) | 41 (21) | 21 (25) | |
Median follow-up (months) | 88 [43-122] | 98 [49-127] | 84 [46-115] | .18 |